220 related articles for article (PubMed ID: 23759589)
1. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
Amatangelo MD; Garipov A; Li H; Conejo-Garcia JR; Speicher DW; Zhang R
Cell Cycle; 2013 Jul; 12(13):2113-9. PubMed ID: 23759589
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
3. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
[TBL] [Abstract][Full Text] [Related]
4. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
5. (-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells.
Ying L; Yan F; Williams BR; Xu P; Li X; Zhao Y; Hu Y; Wang Y; Xu D; Dai J
Clin Exp Pharmacol Physiol; 2018 Jan; 45(1):58-67. PubMed ID: 28925507
[TBL] [Abstract][Full Text] [Related]
6. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.
Garipov A; Li H; Bitler BG; Thapa RJ; Balachandran S; Zhang R
Mol Cancer Res; 2013 Apr; 11(4):360-9. PubMed ID: 23360797
[TBL] [Abstract][Full Text] [Related]
7. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
8. GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells.
Xiong X; Zhang J; Li A; Dai L; Qin S; Wang P; Liu W; Zhang Z; Li X; Liu Z
Cancer Biol Ther; 2020; 21(3):213-222. PubMed ID: 31651209
[TBL] [Abstract][Full Text] [Related]
9. [Effects of Histone Methyltransferase Inhibitors on the Survival, Apoptosis and Cell Cycle of Raji Cells].
Xiao LR; Hou C; Zheng SJ; Guo B; Chen DN; Yan NH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 May; 50(3):305-310. PubMed ID: 31631594
[TBL] [Abstract][Full Text] [Related]
10. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.
Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z
Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257
[TBL] [Abstract][Full Text] [Related]
11. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
[TBL] [Abstract][Full Text] [Related]
12. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Li T; Cai J; Ding H; Xu L; Yang Q; Wang Z
Cancer Biol Ther; 2014 Mar; 15(3):271-8. PubMed ID: 24335192
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni in vitro by GSK343 reduces egg laying and decreases the expression of genes implicated in DNA replication and noncoding RNA metabolism.
Pereira ASA; Amaral MS; Vasconcelos EJR; Pires DS; Asif H; daSilva LF; Morales-Vicente DA; Carneiro VC; Angeli CB; Palmisano G; Fantappie MR; Pierce RJ; Setubal JC; Verjovski-Almeida S
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006873. PubMed ID: 30365505
[TBL] [Abstract][Full Text] [Related]
14. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
15. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.
Li H; Cai Q; Wu H; Vathipadiekal V; Dobbin ZC; Li T; Hua X; Landen CN; Birrer MJ; Sánchez-Beato M; Zhang R
Mol Cancer Res; 2012 Nov; 10(11):1462-72. PubMed ID: 22964433
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹).
Semaan A; Qazi AM; Seward S; Chamala S; Bryant CS; Kumar S; Morris R; Steffes CP; Bouwman DL; Munkarah AR; Weaver DW; Gruber SA; Batchu RB
Pharm Res; 2011 Dec; 28(12):3079-90. PubMed ID: 21818714
[TBL] [Abstract][Full Text] [Related]
17. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.
Bugide S; Gupta R; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301901
[TBL] [Abstract][Full Text] [Related]
18. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.
Seward S; Semaan A; Qazi AM; Gruzdyn OV; Chamala S; Bryant CC; Kumar S; Cameron D; Sethi S; Ali-Fehmi R; Morris R; Bouwman DL; Munkarah AR; Weaver DW; Gruber SA; Batchu RB
Cancer Lett; 2013 Aug; 336(1):53-60. PubMed ID: 23603558
[TBL] [Abstract][Full Text] [Related]
19. EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis.
Ihira K; Dong P; Xiong Y; Watari H; Konno Y; Hanley SJ; Noguchi M; Hirata N; Suizu F; Yamada T; Kudo M; Sakuragi N
Oncotarget; 2017 Feb; 8(8):13509-13520. PubMed ID: 28088786
[TBL] [Abstract][Full Text] [Related]
20. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Bitler BG; Aird KM; Garipov A; Li H; Amatangelo M; Kossenkov AV; Schultz DC; Liu Q; Shih IeM; Conejo-Garcia JR; Speicher DW; Zhang R
Nat Med; 2015 Mar; 21(3):231-8. PubMed ID: 25686104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
